Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome

Despite recent advancements in the therapeutic landscape of acute myeloid leukemia (AML), the prognosis of patients remains poor. Immune check point inhibitors have been investigated in hematological malignancies, including AML; however, the role of T-cell immunoglobulin and mucin domain 3 (TIM-3) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamal, Amany M., Nabih, Nermeen A., Elleboudy, Nooran S., Radwan, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933755/
https://www.ncbi.nlm.nih.gov/pubmed/33692857
http://dx.doi.org/10.3892/ol.2021.12587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933755/
https://www.ncbi.nlm.nih.gov/pubmed/33692857
http://dx.doi.org/10.3892/ol.2021.12587

Ejemplares similares